HUP0402092A3 - Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions - Google Patents

Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions

Info

Publication number
HUP0402092A3
HUP0402092A3 HU0402092A HUP0402092A HUP0402092A3 HU P0402092 A3 HUP0402092 A3 HU P0402092A3 HU 0402092 A HU0402092 A HU 0402092A HU P0402092 A HUP0402092 A HU P0402092A HU P0402092 A3 HUP0402092 A3 HU P0402092A3
Authority
HU
Hungary
Prior art keywords
pyridylmethylaminomethyl
chromane
fluorophenyl
preparation
pharmaceutical compositions
Prior art date
Application number
HU0402092A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0402092A2 publication Critical patent/HUP0402092A2/hu
Publication of HUP0402092A3 publication Critical patent/HUP0402092A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0402092A 2001-07-26 2002-07-10 Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions HUP0402092A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26
PCT/EP2002/007660 WO2003009835A2 (en) 2001-07-26 2002-07-10 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (2)

Publication Number Publication Date
HUP0402092A2 HUP0402092A2 (hu) 2005-02-28
HUP0402092A3 true HUP0402092A3 (en) 2010-06-28

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402092A HUP0402092A3 (en) 2001-07-26 2002-07-10 Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions

Country Status (23)

Country Link
US (1) US7872030B2 (https=)
EP (1) EP1408964B1 (https=)
JP (1) JP2004538289A (https=)
KR (1) KR20040029325A (https=)
CN (1) CN1292749C (https=)
AR (1) AR037496A1 (https=)
AT (1) ATE352302T1 (https=)
AU (1) AU2002355170B2 (https=)
BR (1) BR0211358A (https=)
CA (1) CA2455621C (https=)
CY (1) CY1107616T1 (https=)
DE (1) DE60217870T2 (https=)
DK (1) DK1408964T3 (https=)
ES (1) ES2280602T3 (https=)
HU (1) HUP0402092A3 (https=)
MX (1) MXPA04000775A (https=)
MY (1) MY134059A (https=)
PE (1) PE20030277A1 (https=)
PL (1) PL208258B1 (https=)
PT (1) PT1408964E (https=)
RU (1) RU2297833C2 (https=)
SI (1) SI1408964T1 (https=)
WO (1) WO2003009835A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL367291A1 (en) 2005-02-21
HUP0402092A2 (hu) 2005-02-28
RU2297833C2 (ru) 2007-04-27
AR037496A1 (es) 2004-11-17
AU2002355170B2 (en) 2007-06-07
DE60217870D1 (de) 2007-03-15
DE60217870T2 (de) 2007-11-15
CN1535150A (zh) 2004-10-06
ES2280602T3 (es) 2007-09-16
MY134059A (en) 2007-11-30
KR20040029325A (ko) 2004-04-06
SI1408964T1 (sl) 2007-06-30
PT1408964E (pt) 2007-05-31
CA2455621C (en) 2010-11-16
WO2003009835A3 (en) 2003-08-07
DK1408964T3 (da) 2007-05-21
WO2003009835A2 (en) 2003-02-06
CY1107616T1 (el) 2013-03-13
MXPA04000775A (es) 2004-04-20
US20040171645A1 (en) 2004-09-02
RU2004105844A (ru) 2005-05-10
PL208258B1 (pl) 2011-04-29
PE20030277A1 (es) 2003-03-25
CN1292749C (zh) 2007-01-03
BR0211358A (pt) 2004-09-21
US7872030B2 (en) 2011-01-18
EP1408964B1 (en) 2007-01-24
JP2004538289A (ja) 2004-12-24
ATE352302T1 (de) 2007-02-15
HK1068793A1 (en) 2005-07-29
EP1408964A2 (en) 2004-04-21
CA2455621A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
IL160795A0 (en) Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles
PL356358A1 (en) Solid dosage form of someticone for oral administration
AU2002352974A8 (en) Formulations for oral administration of cromolyn sodium
HUP0600140A3 (en) Prostaglandine derivatives for the treatment of diseases with bone mass loss having ep4 agonist activity and pharmaceutical compositions thereof
IL162293A0 (en) Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
HUP0102160A3 (en) Use of alpha-keto enamine derivatives as ingredients
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
PL368636A1 (en) Pharmaceutical dosage forms of epothilones for oral administration
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
HUP0402092A3 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions
IL161348A (en) Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
EG23169A (en) Method of preparation of macrolide-based pharmaceutical composition for local application in ophthalmology
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0302291A3 (en) Sulfonamide derivatives, process for their preparation and their use for preparation of pharmaceutical compositions
SI1299099T1 (sl) Nova uporaba (r)-(-)-2-5-(4-fluorofenil)-3-piridilmetilaminometil)-kromana in njegovih fiziolosko sprejemljivih soli
HUP0201394A3 (en) Use of pyrrole derivatives for making pharmaceutical compositions
AU2002365665A1 (en) Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
AU2002347360A1 (en) Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
HUP0401798A3 (en) Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
AU2002317063A (en) Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished